Martini, S.; Salmoni, L.; Palladino, R.; Russo, A.; Cuomo, N.; Raddi, A.; Starace, M.; Minichini, C.; Pisaturo, M.; Coppola, N.
Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection. Int. J. Mol. Sci. 2025, 26, 8881.
https://doi.org/10.3390/ijms26188881
AMA Style
Martini S, Salmoni L, Palladino R, Russo A, Cuomo N, Raddi A, Starace M, Minichini C, Pisaturo M, Coppola N.
Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection. International Journal of Molecular Sciences. 2025; 26(18):8881.
https://doi.org/10.3390/ijms26188881
Chicago/Turabian Style
Martini, Salvatore, Lorenzo Salmoni, Roberta Palladino, Antonio Russo, Nunzia Cuomo, Adriana Raddi, Mario Starace, Carmine Minichini, Mariantonietta Pisaturo, and Nicola Coppola.
2025. "Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection" International Journal of Molecular Sciences 26, no. 18: 8881.
https://doi.org/10.3390/ijms26188881
APA Style
Martini, S., Salmoni, L., Palladino, R., Russo, A., Cuomo, N., Raddi, A., Starace, M., Minichini, C., Pisaturo, M., & Coppola, N.
(2025). Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection. International Journal of Molecular Sciences, 26(18), 8881.
https://doi.org/10.3390/ijms26188881
